Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

External analgesic patches

This article was originally published in The Tan Sheet

Executive Summary

OTC "feedback" meeting scheduled for July 8. The meeting was requested by Hisamitsu Pharmaceutical to discuss a testing protocol for its methyl salicylate/menthol/camphor external analgesic patch. FDA asked Hisamitsu to submit safety and efficacy data at a 1994 feedback meeting for inclusion of the patch in the external analgesic final monograph. Hisamitsu submitted a protocol in 1995, and FDA responded with its concerns in 1996. The meeting is to be held at 1:30 p.m. at 9201 Corporate Blvd., Rockville, Md.; contact FDA's Valerie Miguele at (301) 827-2247 for more information. Hisamitsu markets the Salonpas patch in the U.S. in major chains including Walgreen and American Drug Stores. Mentholatum also markets a menthol external analgesic patch, Pain Patch. CNS pulled out of the external analgesic patch business June 30, ending its marketing agreement with Lec Tec for Therapatch...

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS088614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel